

April 17, 2025

<b>BSE Limited</b>	<b>Code: 532321</b>	<b>National Stock Exchange of India Limited</b>	<b>Code: Zyduslife</b>
P J Towers, Dalal Street, <u>Mumbai-400001</u>		Exchange Plaza, C/1, Block G, Bandra-Kurla Complex, Bandra (East), <u>Mumbai-400051</u>	

Ref.: **Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Listing Regulations") read with SEBI Circular dated December 31, 2024**

Dear Sir / Madam,

This is to inform that the United States District Court for the District of Delaware passed an order in the litigation matter pertaining to the validity of patent held by Astellas Pharma Inc., USA ("the **innovator**") for a sustained release formulation of 'mirabegron' marketed in the US by the innovator under the brand name Myrbetriq®.

Necessary details as required under regulation 30 of the Listing Regulations read with SEBI Circular are provided in below table:

Sr. No.	Particulars	Details
1.	Name of the opposing party	Astellas Pharma Inc. ("the <b>innovator</b> ")
2.	Court / tribunal /agency where litigation is filed	United States District Court for the District of Delaware ("the <b>Court</b> ")
3.	Brief description of dispute / litigation	<p>The innovator had filed a case against the Company in the matter pertaining to the validity of its US Patent No. 10,842,780 ("the '<b>780 patent</b>') held by the innovator, for a sustained release formulation of 'mirabegron' marketed in the US by the innovator under the brand name Myrbetriq®.</p> <p>The Court passed an order in favour of the innovator on the validity of the '780 patent. Infringement of the '780 patent, damages, and any additional invalidity theories will be litigated at a consolidated jury trial in 2026.</p>

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878



Sr. No.	Particulars	Details
4.	expected financial implications, if any, due to compensation, penalty etc.;	There is no material financial implication, as on the date of passing the order. We are evaluating the potential impact of the said order on the operations of the Company and the legal remedies available with the Company.
5.	Quantum of claims, if any	None as on date

The submission of intimation got delayed as the stakeholders are spread across global time zones.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY AND COMPLIANCE OFFICER**  
**MEMBERSHIP NO. FCS7063**

**Zydus Lifesciences Limited**

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000  
website : [www.zyduslife.com](http://www.zyduslife.com) | CIN : L24230GJ1995PLC025878

